What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine?

The market is focused on Amgen’s legacy drugs, but one number shows a new, faster-growing core business is already taking over.

For many investors, the story on Amgen (AMGN) is simple: a mature pharmaceutical giant navigating the inevitable decline of its older blockbuster drugs. The narrative is dominated by patent expirations and the pressure they put on future growth. But what if that story is missing the plot?

There is one number that reframes the entire picture. It’s not a pipeline promise or a vague projection. It’s the performance of what Amgen calls its key growth drivers – a specific portfolio of newer drugs and biosimilars. In the most recent quarter, this group had a standout performance.

The Engine That’s Already Running

That portfolio of key drivers grew by 24% in aggregate, year-over-year. That figure alone is strong, but its importance comes from its scale. According to management, these products now generate 70% of the company’s total sales. This isn’t a small, experimental division; it has become the core of Amgen’s business. This group, which includes fast-growing therapies like the cholesterol drug Repatha and a strong rare disease portfolio, is now the company’s primary economic engine.

How This Growth Answers The Biggest Risk

The mechanism here is straightforward but powerful. The biggest risk for Amgen, and the one skeptics rightly point to, is the loss of exclusivity on foundational drugs. In the first quarter, for example, sales of legacy products Prolia and XGEVA combined fell by 32% year-over-year. The company expects that erosion to accelerate.

This is where the 24% growth from the new core becomes so crucial. When the part of your business that makes up 70% of sales is growing that quickly, it creates a powerful mathematical force to offset the decline in the remainder. It demonstrates that the company’s transition has progressed from a plan into a successful reality, one that is already offsetting the very headwind the market fears most.

While the potential of future drugs like MariTide gets much of the attention, the existing portfolio is already doing the heavy lifting. The market’s fixation on the patent cliff may be giving less credit than is due to the new, larger, and faster-growing Amgen that already exists. The key thing to watch now is whether that 24% aggregate growth rate can be sustained, proving this new engine has the durability to power the company forward.

Own The Edge, Not The Single-Stock Risk

Here is the part worth sitting with. The number above is real, but telling a durable strength from a fragile one takes work most investors never have time for, the patient digging that turns a frightening headline into a credible case. Doing that once is hard; doing it across the whole market, every quarter, is a full-time job.

It is the job behind the Trefis High Quality (HQ) Portfolio, a focused set of 30 quality businesses chosen with exactly this kind of research and re-balanced with discipline so no single name decides your outcome. A great number is still just one number, and a rules-based basket of strong ones beats staking everything on a single volatile name. The portfolio has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. If an edge like this is worth acting on, owning quality through a disciplined process is worth a serious look.